Defective Autophagy and mTORC1 Signaling in Myotubularin Null Mice
Open accessThe DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
Autophagy is a vesicular trafficking pathway that regulates the degradation of aggregated proteins and damaged organelles. Initiation of autophagy requires several multiprotein signaling complexes, such as the ULK1 kinase complex and the Vps34 lipid kinase complex, which generates phosphatidylinositol 3-phosphate [PtdIns(3)P] on the forming autophagosomal membrane. Alterations in autophagy have been reported for various diseases, including myopathies. Here we show that skeletal muscle autophagy is compromised in mice deficient in the X-linked myotubular myopathy (XLMTM)-associated PtdIns(3)P phosphatase myotubularin (MTM1). Mtm1-deficient muscle displays several cellular abnormalities, including a profound increase in ubiquitin aggregates and abnormal mitochondria. Further, we show that Mtm1 deficiency is accompanied by activation of mTORC1 signaling, which persists even following starvation. In vivo pharmacological inhibition of mTOR is sufficient to normalize aberrant autophagy and improve muscle phenotypes in Mtm1 null mice. These results suggest that aberrant mTORC1 signaling and impaired autophagy are consequences of the loss of Mtm1 and may play a primary role in disease pathogenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“(ii) X‐linked myotubular myopathies, as defective autophagy is detected in Mtm1 (X‐linked myotubular myopathy gene 1)‐deficient mouse muscle (Fetalvero et al, 2013)”
From Autophagy in major human diseases (2021) · cites this paper as Fetalvero et al, 2013
In the citing paper
“Myopathic defects associated with impaired autophagic flux and abnormal mitochondria”
From Autophagy in major human diseases (2021) · cites this paper as Fetalvero et al (2013)
Citations
Cites
AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1
Kim, J., Kundu, M., Viollet, B., & Guan, K.-L. (2011) · Nature Cell Biology · doi:10.1038/ncb2152 · Cited by 7,227 · cited 1×
“One way in which mTOR is believed to inhibit autophagy is direct phosphorylation of ULK1 (12–14), and a recent study identified ULK1 as an mTOR-regulated phosphorylation site (45).”
BackgroundAutophagy in the Pathogenesis of Disease
Levine, B., & Kroemer, G. (2008) · Cell · doi:10.1016/j.cell.2007.12.018 · Cited by 7,069 · cited 4×
“Nutrient limitation represents one of the major ways in which autophagy is activated, and in this context, the recycling of cellular components provides the cell with a source of ATP and amino acids to maintain normal homeostatic processes (1).”
BackgroundInfluentialTOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787 · cited 9×
“This complex is regulated by mTOR (12–14), which itself assembles into two multiprotein complexes termed mTORC1 and mTORC2 (15).”
BackgroundInfluentialPankiv, S., Clausen, T. H., Lamark, T., Brech, A., Bruun, J.-A., Outzen, H., Øvervatn, A., Bjørkøy, G., & Johansen, T. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702824200 · Cited by 4,578 · cited 2×
“These observations are consistent with previous reports showing that elevated levels of p62, a key molecule involved in the targeting of ubiquitinated proteins to the autophagosome, contribute to the aggregation of ubiquitinated proteins when autophagic flux is reduced (4, 41).”
BackgroundResultSuppression of basal autophagy in neural cells causes neurodegenerative disease in mice
Hara, T., Nakamura, K., Matsui, M., Yamamoto, A., Nakahara, Y., Suzuki-Migishima, R., Yokoyama, M., Mishima, K., Saito, I., Okano, H., et al. (2006) · Nature · doi:10.1038/nature04724 · Cited by 3,882
Loss of autophagy in the central nervous system causes neurodegeneration in mice
Komatsu, M., Waguri, S., Chiba, T., Murata, S., Iwata, J.-I., Tanida, I., Ueno, T., Koike, M., Uchiyama, Y., Kominami, E., et al. (2006) · Nature · doi:10.1038/nature04723 · Cited by 3,500 · cited 8×
“MTM1 and related phosphatases can dephosphorylate PtdIns(3)P in vitro (25) and may therefore oppose the action of Vps34.”
BackgroundMethodInfluentialTFEB Links Autophagy to Lysosomal Biogenesis
Settembre, C., Di Malta, C., Polito, V. A., Arencibia, M. G., Vetrini, F., Erdin, S., Erdin, S. U., Huynh, T., Medina, D., Colella, P., et al. (2011) · Science · doi:10.1126/science.1204592 · Cited by 3,365
Wallace, D. C. (2005) · Annual Review of Genetics · doi:10.1146/annurev.genet.39.110304.095751 · Cited by 3,185 · cited 1×
“damage (50), and changes in mitochondrial content and function”
BackgroundKim, D.-H., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2002) · Cell · doi:10.1016/s0092-8674(02)00808-5 · Cited by 2,986
The Rag GTPases Bind Raptor and Mediate Amino Acid Signaling to mTORC1
Sancak, Y., Peterson, T. R., Shaul, Y. D., Lindquist, R. A., Thoreen, C. C., Bar-Peled, L., & Sabatini, D. M. (2008) · Science · doi:10.1126/science.1157535 · Cited by 2,773 · cited 2×
“Recent reports suggest that activation of mTOR in response to amino acids requires redistribution of mTOR to lysosomes (56), where it encounters its upstream activator Rheb (56, 57).”
Background
Cited by
Autophagy in major human diseases
Klionsky, D. J., Petroni, G., Amaravadi, R. K., Baehrecke, E. H., Ballabio, A., Boya, P., Bravo‐San Pedro, J. M., Cadwell, K., Cecconi, F., Choi, A. M. K., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2021108863 · Cited by 1,585
Phosphatidylinositol 3-phosphates—at the interface between cell signalling and membrane traffic
Marat, A. L., & Haucke, V. (2016) · The EMBO Journal · doi:10.15252/embj.201593564 · Cited by 299
“As an example, MTM1-deficient muscles from knock-out mice display elevated mTORC1 activity that persists after starvation resulting in a defect in autophagy (Fetalvero et al , 2013).”
Congenital myopathies: disorders of excitation–contraction coupling and muscle contraction
Jungbluth, H., Treves, S., Zorzato, F., Sarkozy, A., Ochala, J., Sewry, C., Phadke, R., Gautel, M., & Muntoni, F. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.191 · Cited by 280
The intricate regulation and complex functions of the Class III phosphoinositide 3-kinase Vps34
Backer, J. M. (2016) · Biochemical Journal · doi:10.1042/bcj20160170 · Cited by 238
Regulation of autophagy by amino acids and MTOR-dependent signal transduction
Meijer, A. J., Lorin, S., Blommaart, E. F., & Codogno, P. (2015) · Amino Acids · doi:10.1007/s00726-014-1765-4 · Cited by 190
“The observation that in skeletal muscle of mice deficient of myotubularin, the lipid phosphatase responsible for the degradation of PI(3)P, autophagy is defective and MTOR overactivated (Fetalvero et al. 2013) may be explained similarly.”
BackgroundSkeletal muscle autophagy: a new metabolic regulator
Neel, B. A., Lin, Y., & Pessin, J. E. (2013) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.09.004 · Cited by 178
“MTM1 has the same lipid phosphatase activity as MTMR14, and the knockout mouse model presents with an activation of skeletal muscle autophagy [29,30].”
BackgroundReducing dynamin 2 expression rescues X-linked centronuclear myopathy
Cowling, B. S., Chevremont, T., Prokic, I., Kretz, C., Ferry, A., Coirault, C., Koutsopoulos, O., Laugel, V., Romero, N. B., & Laporte, J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci71206 · Cited by 151
“Mtm1 -knockout mice or mice with knockin of a patient mutation both recapitulate the CNM phenotype with classical histological features including abnormal organelle positioning, mislocalization of nuclei, and muscle atrophy, associated with a corresponding reduction in muscle strength (10–12).”
Pathogenic Mechanisms in Centronuclear Myopathies
Jungbluth, H., & Gautel, M. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00339 · Cited by 130
“AGING NEUROSCIENCE REVIEW ARTICLE published: 19 December 2014 doi: 10.3389/fnagi.2014.00339 Pathogenic mechanisms in centronuclear myopathies”
BackgroundResultInfluentialWhite, Z., Terrill, J., White, R. B., McMahon, C., Sheard, P., Grounds, M. D., & Shavlakadze, T. (2016) · Skeletal Muscle · doi:10.1186/s13395-016-0117-3 · Cited by 117
Deneubourg, C., Ramm, M., Smith, L. J., Baron, O., Singh, K., Byrne, S., Duchen, M. R., Gautel, M., Eskelinen, E., Fanto, M., et al. (2021) · Autophagy · doi:10.1080/15548627.2021.1943177 · Cited by 120
“disorders, in particular lysosomal disorders and those due to defects in vesicular and membrane trafficking [178].”
BackgroundPIK3C2B inhibition improves function and prolongs survival in myotubular myopathy animal models
Sabha, N., Volpatti, J. R., Gonorazky, H., Reifler, A., Davidson, A. E., Li, X., Eltayeb, N. M., Dall’Armi, C., Di Paolo, G., Brooks, S. V., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86841 · Cited by 106
“that Mtm1 KO mice have improved muscle mass when treated with an mTOR inhibitor (AZD8055) that increases autophagic flux (37).”
BackgroundEndosomal lipid signaling reshapes the endoplasmic reticulum to control mitochondrial function
Jang, W., Puchkov, D., Samsó, P., Liang, Y., Nadler-Holly, M., Sigrist, S. J., Kintscher, U., Liu, F., Mamchaoui, K., Mouly, V., et al. (2022) · Science · doi:10.1126/science.abq5209 · Cited by 100
“Although mechanistic target of rapamycin complex 1 (mTORC1) activity was elevated in fed MTM1 KO cells [consistent with observations in MTM1 KO mice (34)], loss of MTM1 did not affect suppression of mTORC1 activity in starved cells (fig.”
BackgroundDefective lysosome reformation during autophagy causes skeletal muscle disease
McGrath, M. J., Eramo, M. J., Gurung, R., Sriratana, A., Gehrig, S. M., Lynch, G. S., Lourdes, S. R., Köentgen, F., Feeney, S. J., Lazarou, M., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci135124 · Cited by 96
“Sustained AKT/mTOR activation causes muscle disease by suppressing autophagosome formation and inhibiting autophagy; however, changes to lysosomal homeostasis were not reported (7, 51, 52).”
BackgroundLawlor, M. W., & Dowling, J. J. (2021) · Neuromuscular Disorders · doi:10.1016/j.nmd.2021.08.003 · Cited by 96
Ravenscroft, G., Laing, N. G., & Bönnemann, C. G. (2014) · Brain · doi:10.1093/brain/awu368 · Cited by 97
“Similarly, LC3-I, LC3-II, p62 and LAMP2 proteins were more abundant in Mtm1 / muscle than wild-type; levels of phosphorylated S6 and Akt were also elevated in Mtm1 / muscle (Fetalvero et al., 2013).”
BackgroundLysosomal Two-pore Channel Subtype 2 (TPC2) Regulates Skeletal Muscle Autophagic Signaling
Lin, P.-H., Duann, P., Komazaki, S., Park, K. H., Li, H., Sun, M., Sermersheim, M., Gumpper, K., Parrington, J., Galione, A., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.608471 · Cited by 83
Triadopathies: An Emerging Class of Skeletal Muscle Diseases
Dowling, J. J., Lawlor, M. W., & Dirksen, R. T. (2014) · Neurotherapeutics · doi:10.1007/s13311-014-0300-3 · Cited by 87
“For example, MTM1 has been implicated as a regulator of autophagy and of the desmin intermediate filament network [59–61].”
BackgroundAl‐Qusairi, L., Prokic, I., Amoasii, L., Kretz, C., Messaddeq, N., Mandel, J., & Laporte, J. (2013) · The FASEB Journal · doi:10.1096/fj.12-220947 · Cited by 76
“(52) reported the analysis of a different Mtm1-null mouse model and suggested that the increase of mTOR signaling in this model was correlated with inhibition of autophagy.”
BackgroundMYTHO is a novel regulator of skeletal muscle autophagy and integrity
Leduc‐Gaudet, J., Franco‐Romero, A., Cefis, M., Moamer, A., Broering, F. E., Milan, G., Sartori, R., Chaffer, T. J., Dulac, M., Marcangeli, V., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36817-1 · Cited by 79
Autophagy in the Regulation of Tissue Differentiation and Homeostasis
Perrotta, C., Cattaneo, M. G., Molteni, R., & Palma, C. D. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.602901 · Cited by 79
“In this regard, many other examples indicate that muscle is particularly susceptible to autophagy dysregulation (Dobrowolny et al., 2008; Sarparanta et al., 2012; Fetalvero et al., 2013).”
BackgroundSkeletal Muscle Pathology in X-Linked Myotubular Myopathy: Review With Cross-Species Comparisons
Lawlor, M. W., Beggs, A. H., Buj-Bello, A., Childers, M. K., Dowling, J. J., James, E. S., Meng, H., Moore, S. A., Prasad, S., Schoser, B., et al. (2016) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlv020 · Cited by 70
“MTM1 MICE An Mtm1 mutant mouse with a truncating mutation in exon 1 of Mtm1 has been described in a single publication (23).”
BackgroundAutophagy Defects in Skeletal Myopathies
Margeta, M. (2019) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012419-032618 · Cited by 78
Shelton, G. D., Rider, B. E., Child, G., Tzannes, S., Guo, L. T., Moghadaszadeh, B., Troiano, E. C., Haase, B., Wade, C. M., & Beggs, A. H. (2015) · Skeletal Muscle · doi:10.1186/s13395-014-0025-3 · Cited by 69
“Although prominent upregulation of markers of autophagy has not yet been described as a general feature of XLMTM in humans, recent studies on two myotubularin-deficient mouse models have revealed significant abnormalities of the autophagy-lysosomal pathway [38,39].”
BackgroundTamoxifen therapy in a murine model of myotubular myopathy
Maani, N., Sabha, N. S., Rezai, K., Ramani, A. K., Groom, L. A., Eltayeb, N., Mavandadnejad, F., Pang, A., Russo, G., Brudno, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07057-5 · Cited by 75
Gómez, R., Cowling, B. S., & Laporte, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111377 · Cited by 68
“In addition, decreased expression of oxidative phosphorylation genes and decreased COX activity was present in the Mtm1 gene trap model [61].”
BackgroundMethodInfluentialAUTEN-67, an autophagy-enhancing drug candidate with potent antiaging and neuroprotective effects
Papp, D., Kovács, T., Billes, V., Varga, M., Tarnóci, A., Hackler, L., Puskás, L. G., Liliom, H., Tárnok, K., Schlett, K., et al. (2016) · Autophagy · doi:10.1080/15548627.2015.1082023 · Cited by 62
Activation Mechanisms of the VPS34 Complexes
Ohashi, Y. (2021) · Cells · doi:10.3390/cells10113124 · Cited by 67
Role of autophagy in muscle disease
Franco‐Romero, A., & Sandri, M. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.101041 · Cited by 70
White, Z., White, R. B., McMahon, C., Grounds, M. D., & Shavlakadze, T. (2016) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2016.06.012 · Cited by 59
Dynamin 2 (DNM2) as Cause of, and Modifier for, Human Neuromuscular Disease
Zhao, M., Maani, N., & Dowling, J. J. (2018) · Neurotherapeutics · doi:10.1007/s13311-018-00686-0 · Cited by 65
Single Intramuscular Injection of AAV-shRNA Reduces DNM2 and Prevents Myotubular Myopathy in Mice
Tasfaout, H., Lionello, V. M., Kretz, C., Koebel, P., Messaddeq, N., Bitz, D., Laporte, J., & Cowling, B. S. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.02.008 · Cited by 67
“MTM1 is a phosphoinositide phosphatase involved in key cellular processes, including endosomal trafficking,(10) excitation contraction coupling,(11,12) intermediate filament organization,(13) neuromuscular junction (NMJ) structure,(14,15) satellite cell proliferation,(16) apoptosis,(16,17) and autophagy.(18,19) Mutati…”
BackgroundTamoxifen prolongs survival and alleviates symptoms in mice with fatal X-linked myotubular myopathy
Gayi, E., Neff, L. A., Massana-Muñoz, X., Ismail, H. M., Sierra, M., Mercier, T., Decosterd, L. A., Laporte, J., Cowling, B. S., Dorchies, O. M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07058-4 · Cited by 63
Castets, P., Frank, S., Sinnreich, M., & Rüegg, M. A. (2016) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-160153 · Cited by 49
“While LC3 levels were increased in Mtm1-null mouse muscle, LC3II lipidation was impaired upon starvation of the mutant mice [187], suggesting that autophagy induction is blocked.”
BackgroundMendelian disorders of PI metabolizing enzymes
Staiano, L., Leo, M. G. D., Persico, M., & Matteis, M. A. D. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.12.001 · Cited by 58
Centronuclear myopathies under attack: A plethora of therapeutic targets
Tasfaout, H., Cowling, B. S., & Laporte, J. (2018) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-180309 · Cited by 52
“neuromuscular junction (NMJ) structure [16, 17], 52 satellite cell proliferation [18–20], and autophagy 53 [21, 22].”
BackgroundMethodInfluentialChromosomal Instability and Phosphoinositide Pathway Gene Signatures in Glioblastoma Multiforme
Waugh, M. G. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-9034-9 · Cited by 48
“ing [80–82] and autophagy [78, 83, 84], it is possible that loss of this gene combination results in profound defects in the intracellular trafficking and degradation of receptor tyrosine”
The role of lipids in autophagy and its implication in neurodegeneration
Hernández-Díaz, S., & Soukup, S. (2020) · Cell Stress · doi:10.15698/cst2020.07.225 · Cited by 42
“For instance, the absence of MTM1 results in activation of mTORC1 [95] and several myotubularin-related phosphatases are reported to control different stages of autophagy,”
BackgroundThe expanding spectrum of neurological disorders of phosphoinositide metabolism
Volpatti, J. R., Al-Maawali, A. A., Smith, L., Alhashim, A. H., Brill, J. A., & Dowling, J. J. (2019) · Disease Models & Mechanisms · doi:10.1242/dmm.038174 · Cited by 44
“In muscle tissue, loss of MTM1 is associated with PtdIns3P accumulation (Fetalvero et al., 2013; Pierson et al., 2012; Sabha et al., 2016).”
Disrupted autophagy undermines skeletal muscle adaptation and integrity
Jokl, E. J., & Blanco, G. (2016) · Mammalian Genome · doi:10.1007/s00335-016-9659-2 · Cited by 46
“…Enhanced mTORC1 signalling resulting in inhibited autophagy Choi et al. (2012) MTM1 X-linked tubular myopathy Defects in autophagy inhibition Fetalvero et al. (2013) MTMR14 Congenital disease centronuclear myopathy Defects in autophagy inhibition Fetalvero et al. (2013), Tosch et…”
InfluentialPulido, R., Stoker, A. W., & Hendriks, W. J. A. J. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt347 · Cited by 42
Hepatobiliary disease in XLMTM: a common comorbidity with potential impact on treatment strategies
D’Amico, A., Longo, A., Fattori, F., Tosi, M., Bosco, L., Testa, M. B. C., Paglietti, M. G., Cherchi, C., Carlesi, A., Mizzoni, I., et al. (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-021-02055-1 · Cited by 35
Myotubularin-related protein 7 inhibits insulin signaling in colorectal cancer
Weidner, P., Söhn, M., Gutting, T., Friedrich, T., Gaiser, T., Magdeburg, J., Kienle, P., Ruh, H., Hopf, C., Behrens, H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10466 · Cited by 41
“Hence, MTMR7 did not block single mTORC1/2 complexes, as described for MTM1 [19, 20] or MTMR3 [21], what would have abrogated phosphorylation exclusively on either SER473, which is part of the AKT-mTORC2 feed forward loop, or THR308, which is targeted by PI3K-PDK1.”
BackgroundA neurogenic perspective of Sarcopenia: time course study of sciatic nerves from aging mice
Krishnan, V. S., White, Z., McMahon, C. D., Hodgetts, S. I., Fitzgerald, M., Shavlakadze, T., Harvey, A. R., & Grounds, M. D. (2016) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlw019 · Cited by 32
“LC3II itself is degraded by autophagy and accumulation of LC3II along with accumulation of LAMP proteins is seen in cases where autophagy is impaired (108).”
BackgroundHepatotoxicity in Adeno-Associated Viral Vector Gene Therapy
Jagadisan, B., & Dhawan, A. (2023) · Current Hepatology Reports · doi:10.1007/s11901-023-00624-5 · Cited by 36
“Hypothesis on the mechanism of liver manifestations include defects in autophagy and the impaired lipid layer trafficking [73].”
Ross, J. A., Tasfaout, H., Levy, Y., Morgan, J. E., Cowling, B. S., Laporte, J., Zanoteli, E., Romero, N. B., Lowe, D. A., Jungbluth, H., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01048-8 · Cited by 28
Expression of the neuropathy-associated MTMR2 gene rescues MTM1-associated myopathy
Raess, M. A., Cowling, B. S., Bertazzi, D. L., Kretz, C., Rinaldi, B., Xuereb, J.-M., Kessler, P., Romero, N. B., Payrastre, B., Friant, S., et al. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx258 · Cited by 35
“Other therapeutic proof-of-concepts have been reported that do not target PPIn normalization, such as downregulation/ normalization of DNM2 (31), expression of catalytic dead MTM1C375S (15) or inhibition of autophagy (38).”
BackgroundTherapeutic approaches in different congenital myopathies
Gineste, C., & Laporte, J. (2022) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2022.102328 · Cited by 33
Dupont, J.-B., Guo, J., Renaud-Gabardos, E., Poulard, K., Latournerie, V., Lawlor, M. W., Grange, R. W., Gray, J. T., Buj‐Bello, A., Childers, M. K., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.10.018 · Cited by 30
“In XLMTM mice, these characteristics correlate with dysregulated PI3K/Akt/mTOR signaling and abnormal autophagy.(29,30,44,45) More recently, another study reported the downregulation of the myostatin pathway in Mtm1-KO mice, which could be a compensatory mechanism to counter muscle hypotrophy.”
BackgroundVolpatti, J. R., Ghahramani-Seno, M. M., Mansat, M., Sabha, N. S., Sarikaya, E., Goodman, S. J., Chater‐Diehl, E., Celik, A., Pannia, E., Froment, C., et al. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02468-7 · Cited by 25
“It is also associated with alteration of several cellular pathways, including autophagy [1, 25, 28], proteasomal turnover [1, 30], mitochondrial oxidative phosphorylation [34], and integrin trafficking [48].”
Joubert, R., Vignaud, A., Le, M., Moal, C., Messaddeq, N., & Buj-Bello, A. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt038 · Cited by 24
“(22) reported impaired autophagy and aberrant mTORC1 signaling in Mtm1 null mice.”
BackgroundMetti, S., Gambarotto, L., Chrisam, M., Spina, M. L., Baraldo, M., Braghetta, P., Blaauw, B., & Bonaldo, P. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.580933 · Cited by 25
Franco‐Romero, A., Sandri, M., & Schiaffino, S. (2024) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a041565 · Cited by 27
Merlini, L., & Nishino, I. (2014) · Neuromuscular Disorders · doi:10.1016/j.nmd.2014.03.009 · Cited by 28
Djeddi, S., Reiss, D. J., Menuet, A., Freismuth, S., Neves, J. D. C., Djerroud, S., Massana-Muñoz, X., Sosson, A.-S., Kretz, C., Raffelsberger, W., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.04.033 · Cited by 26
Natural history of a mouse model of X-linked myotubular myopathy
Sarikaya, E., Sabha, N. S., Volpatti, J. R., Pannia, E., Maani, N., Gonorazky, H. D., Celik, A., Liang, Y., Onofre-Oliveira, P. C. G., & Dowling, J. J. (2022) · Disease Models & Mechanisms · doi:10.1242/dmm.049342 · Cited by 24
“These include gene replacement therapy (Childers et al., 2014), enzyme replacement therapy (Lawlor et al., 2013), PIK3C2B lowering (Sabha et al., 2016) and pathway modifiers such as rapamycin (Fetalvero et al., 2013).”
Tamoxifen improves muscle structure and function of Bin1- and Dnm2-related centronuclear myopathies
Gineste, C., Simon, A., Braun, M., Reiss, D. J., & Laporte, J. (2022) · Brain · doi:10.1093/brain/awac489 · Cited by 18
Mercier, L., Böhm, J., Fekonja, N., Allio, G., Lutz, Y., Koch, M., Goetz, J. G., & Laporte, J. (2016) · IntraVital · doi:10.1080/21659087.2016.1168553 · Cited by 21
Jungbluth, H., Wallgren‐Pettersson, C., & Laporte, J. (2013) · Neuromuscular Disorders · doi:10.1016/j.nmd.2013.08.006 · Cited by 16
SPEG binds with desmin and its deficiency causes defects in triad and focal adhesion proteins
Luo, S., Li, Q., Lin, J., Murphy, Q., Marty, I., Zhang, T., Kazerounian, S., & Agrawal, P. B. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa276 · Cited by 11
“Based on findings from these models, several pathogenic mechanisms have been suggested, including abnormalities of triads and excitation–contraction (E–C) coupling (17,27), as well as defects in autophagy (21,23), and of the neuromuscular junction (28,29), satellite cells (30), integrin trafficking (15), mitochondria…”
BackgroundA model of muscle atrophy based on live microscopy of muscle remodelling inDrosophilametamorphosis
Kuleesha, Y., Puah, W. C., & Wasser, M. (2016) · Royal Society Open Science · doi:10.1098/rsos.150517 · Cited by 18
“mice for MTM1, a gene involved in CNM, showed an impairment of autophagy in conjunction with centrally located nuclei [49,50].”
Capalbo, G., Müller-Kuller, T., Koschmieder, S., Klein, H., Ottmann, O. G., Hoelzer, D. F., & Scheuring, U. J. (2013) · Oncology Reports · doi:10.3892/or.2013.2716 · Cited by 14
Vinette, V., Aubry, I., Insull, H., Uetani, N., Hardy, S., & Tremblay, M. L. (2021) · The FASEB Journal · doi:10.1096/fj.202100207r · Cited by 11
Silva‐Rojas, R., Pérez‐Guàrdia, L., Lafabrie, E., Moulaert, D., Laporte, J., & Böhm, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23136968 · Cited by 12
Longo, G., Russo, S., Novelli, G., Sangiuolo, F. C., & D’Apice, M. R. (2015) · Clinical Genetics · doi:10.1111/cge.12674 · Cited by 11
“Other studies show even alterations in skeletal muscle autophagy (7), including an increase in ubiquitin aggregates and abnormal mitochondria, that are typical in XLMTM patients’ muscles (2).”
BackgroundTafaleng, E. N., Li, J., Wang, Y., Hidvegi, T., Soto-Gutierrez, A., Locke, A. E., Nicholas, T. J., Wang, Y.-C., Pak, S. C., Cho, M. H., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000865 · Cited by 8
“[19,20] It has an MAF of 0.003 in the control cohort.”
BackgroundInfluentialAdeno‐associated viral vector gene therapy: Challenges for the paediatric hepatologist
Jagadisan, B., & Dhawan, A. (2024) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1002/jpn3.12326 · Cited by 9
Mass Assays to Quantify Bioactive PtdIns3P and PtdIns5P During Autophagic Responses
Viaud, J., Chicanne, G., Solinhac, R., Hnia, K., Gaits‐Iacovoni, F., & Payrastre, B. (2016) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2016.09.061 · Cited by 6
Zanellati, M. C., & Cohen, S. (2022) · Science · doi:10.1126/science.adf5112 · Cited by 4
Interplay between myotubularins and Ca2+ homeostasis
Dai, N., Groenendyk, J., & Michalak, M. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2024.119739 · Cited by 4
Li, X., Zheng, J., Su, J., Wang, L., Luan, L., Wang, T., Bai, F., Zhong, Q., & Gong, Q. (2024) · Autophagy · doi:10.1080/15548627.2024.2394302 · Cited by 6
“Apart from its critical function in PtdIns3P-to-PtdIns4P conversion that enables endosomal exocytosis [37], MTM1 is also required for autophagy; Mtm1 - deficient mice had a reduced autophagic flux and accumulated damaged mitochondria in the muscle [38].”
Duarte, D. M., Lima, M. B. D. S., & Sepodes, B. M. N. (2020) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2020.104810 · Cited by 4
X-linked myotubular myopathy: an untreated treatable disease
Martín, C., & Servais, L. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2473430 · Cited by 3
“…intron 1, leading to a truncated, nonfunctional version of MTM1 and exhibiting similar muscle pathology compared to that observed in MTM1 −/y mice [36]; (4) MTM1 Δ5/y and MTM1 Δ7/y mice, generated by deletions of 5 and 7 base pairs, respectively, within the MTM1 gene, display similar features…”
InfluentialAberrant lysosomal dynamics disrupt myogenesis via mTORC1 signalling in X-linked myotubular myopathy
Kora, K., Yoshida, T., Yokoyama, A., Fujiwara, K., Yano, N., Kayaki, T., Kajimoto, S., Nishikawa, K., Sakurai, H., & Takita, J. (2025) · Brain · doi:10.1093/brain/awaf278 · Cited by 2
X-Linked Myotubular Myopathy and Mitochondrial Function in Muscle and Liver Samples
Inoue, K., Kato, T., Terasaki, E., Ishihara, M., Fujii, T., Aida, Y., & Murayama, K. (2024) · Neuropediatrics · doi:10.1055/s-0044-1788333 · Cited by 2
“4 Although muscle involvement is the most dramatic manifestation inpatients with XLMTM, long-term survivorsshow additional organ manifestations, such as elevation of serum aminotransferases and hepatic peliosis, suggesting that XLMTM is a multisystem disorder.”
Regulation of Autophagy by Amino Acids
Lorin, S., Meijer, A. J., & Codogno, P. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801032-7.00002-2 · Cited by 2
Gene Therapy for X-Linked Myotubular Myopathy
Dupont, J.-B., Lawlor, M. W., & Childers, M. K. (2019) · Springer eBooks · doi:10.1007/978-3-030-03095-7_32 · Cited by 2
Colombo, S., Cowling, B. S., Eyler, L. T., Nijkamp, D. M., Freitag, C., Thielemans, L. A., Bouman, K., Baets, J., Vissing, J., Quinlivan, R. C. M., et al. (2025) · Journal of Neuromuscular Diseases · doi:10.1177/22143602251329215 · Cited by 1
Duckhorn, J. C., Kim, D. K., & Huang, Y. A. (2025) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-25-00243 · Cited by 2
“Similarly, Mtm1-null mice show increased autophagosomes and reduced autophagic flux, with elevated LC3-I/II and p62 levels (Al-Qusairi et al., 2013; Fetalvero et al., 2013).”
Lack of myotubularin phosphatase activity is the main cause of X-linked myotubular myopathy
Moschovaki-Filippidou, F., Kretz, C., Reiss, D., Chicanne, G., Payrastre, B., & Laporte, J. (2025) · JCI Insight · doi:10.1172/jci.insight.189286 · Cited by 1
“In mice, 3 different mouse lines were generated through either a KO approach ( Mtm1 –/y ) (30), a gene trap ( Mtm1 gt / y ) (31), or a knock-in of a patient mutation ( Mtm1 p.R69C) (32), all leading to the loss of MTM1.”
InfluentialLysosomal phosphoinositide turnover acts upstream of RagGTPase–mTORC1 and controls muscle growth
Picot, M., Hifdi, N., Vaucourt, M., Mansat, M., Li, P., Singer, I. I., Chicanne, G., Stella, A., Shen, K., Miceli, C., et al. (2026) · Nature Metabolism · doi:10.1038/s42255-026-01484-1 · Cited by 2
Role of Phosphoinositides in Membrane Traffic
Sheffield, D. A., Gurung, R., & Mitchell, C. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-394447-4.20051-5 · Cited by 1
2 Month‐Old Male with Hypotonia
Tanboon, J., Viravan, S., Hayashi, Y. K., Nishino, I., & Sangruchi, T. (2015) · Brain Pathology · doi:10.1111/bpa.12284
“Severe X-linked myotubular myopathy (XLMTM) is caused by mutations in myotubularin 1 gene (MTM1) on Xq28 encoding for 3′-phosphoinositides lipid phosphatase.”
BackgroundInfluentialSkeletal muscle regeneration in DNM2-related centronuclear myopathy
de Almeida, C. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.41.2019.tde-27082019-090701
Clinical Characteristics and Neurologic Outcomes of X-Linked Myotubular Myopathy
Woo, H., Lee, S., Han, J. Y., Kim, W. J., Kim, M. J., Seong, M., Kim, S. Y., Cho, A., Lim, B. C., Kim, K. J., et al. (2022) · Annals of Child Neurology · doi:10.26815/acn.2022.00171
Role of Phosphoinositides in Membrane Traffic
Sheffield, D. A., Gurung, R., & Mitchell, C. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-821618-7.20051-5
Сухарева, К. С., Mikhaleva, A. I., Гурщенков, А. В., Zaĭtsev, V. V., Kozyreva, A. A., Andreeva, S. E., Gavrilova, L. S., Моисеева, О. М., Kostareva, A. A., Гребенник, В. К., et al. (2024) · Translational Medicine · doi:10.18705/2311-4495-2024-11-2-170-180
Autophagy Assessment in Diagnostic Pathology: Focus on Skeletal Myopathies
Ramani, B., & Margeta, M. (2025) · Learning materials in biosciences · doi:10.1007/978-3-031-88121-3_9
Papazoglou, I. (2013) · theses.fr (ABES) · doi:10.70675/06d278b5zf0a0z456dz9c4cz9dc680b45fd3 · Cited by 1
Nattarayan, V. (2019) · theses.fr (ABES) · doi:10.70675/ae3ccc54z0dc2z41eaz9235z249d0e67d964
Signalisation et implication des phosphoinositides dans la myopathie myotubulaire liée à l'X
Mansat, M. (2022) · theses.fr (ABES) · doi:10.70675/ff8ec5a0z1358z4abdzac6az4cc19fb4f41e
Shearer, A., Brooks, M. L., Chen, M. M., Samarakoon, T. B., Hsieh, J., Kondakci, G., Perola, E., Brubaker, J. D., Fetalvero, K. M., Schalm, S. S., et al. (2026) · JCI Insight · doi:10.1172/jci.insight.198568
“Deficiency of myotubularin has also been linked to elevated mTORC1 activity, leading to a disruption in the connection between starvation and the initiation of autophagy (27).”
Self-citationGaillard, J., Malleval, C., Dauvois, C., Gueloua, L., Schreiber, J., Kretz‐Remy, C., Gangloff, Y., Allard, B., Berthier, C., & Jacquemond, V. (2026) · Autophagy · doi:10.1080/15548627.2026.2693256
“They though include some severe disease conditions that compromise basic muscle function such as myotubular myopathy [18], which is associated with altered autophagic flux [14,20].”
Metadata
- Authors
- Fetalvero, K. M., Yu, Y., Goetschkes, M., Liang, G., Valdez, R. A., Gould, T., Triantafellow, E., Bergling, S., Loureiro, J., Eash, J., Lin, V., Porter, J. A., Finan, P. M., Walsh, K., Yang, Y., Mao, X., & Murphy, L. O.
- Affiliations
- Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, USA
- Metabolism and Pharmacokinetics, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, USA
- Novartis Institutes for BioMedical Research (CH)
- Boston University (US)
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 2013-01-01
- Volume
- 33
- Issue
- 1
- Pages
- 98-110
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- PMC
- PMC3536306
- OpenAlex
- W2108486519
- Cited by
- 96
- References
- 61
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 7 · 2023: 2 · 2022: 9 · 2021: 9 · 2020: 7 · 2019: 6 · 2018: 8 · 2017: 2 · 2016: 14 · 2015: 6 · 2014: 9 · 2013: 7
- FWCI
- 5.25
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Molecular and Cellular Biology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (R01AG034972)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
- Keywords
- autophagy, mTORC1 signaling, myotubularin, MTM1, X-linked myotubular myopathy, skeletal muscle, mitochondrial abnormalities, starvation, mTOR inhibition, autophagosomal membrane
- MeSH terms
- Mechanistic Target of Rapamycin Complex 1, Animals, Autophagy, Mice, Inbred C57BL, Mice, Mutant Strains, Mitochondria, Proteins, Signal Transduction, Phosphatidylinositol Phosphates, Muscle, Skeletal, Sirolimus, Myopathies, Structural, Congenital, Ubiquitin, Multiprotein Complexes, Mice, Protein Tyrosine Phosphatases, Non-Receptor, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.